NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTideTM technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.
June 22 - 24, 2020
Virtual Meeting II, Sessions Available Online
NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
"Utilising our proprietary ProTide technology platform we are developing new medicines designed to overcome key cancer resistance mechanisms and improve the survival outcomes for patients."
Designed to overcome the key cancer resistance mechanisms associated with gemcitabine. Currently in a Phase III study for patients with biliary tract cancer.
Designed to overcome the limitations associated with 5-FU. Currently being investigated in patients with advanced colorectal cancer.
A transformation of 3’-dexoxyadenosine, a novel nucleoside analog with a unique anti-cancer modes of action. Currently in a Phase I study.
NuCana's ProTide technology is a powerful platform generating new anti-cancer medicines designed to overcome the key cancer resistance mechanisms.
We take a scientifically driven approach to designing ProTides, which we believe have the potential to provide highly efficacious cancer therapies with improved tolerability.
NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic
NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference
Wednesday, June 3, 2020